A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma (study 205715)

Published: 25-07-2016
Last updated: 15-04-2024

Primary:To evaluate the effects of FF/UMEC/VI on lung function compared with FF/VI after 24 weeks of treatmentSecondary:To assess the efficacy (exacerbations), FEV1 3h post dose, asthma symptoms, safety and tolerability.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Bronchial disorders (excl neoplasms)
Study type	Interventional

Summary

ID

NL-OMON45467

Source
ToetsingOnline

Brief title
study 205715

Condition

- Bronchial disorders (excl neoplasms)

Synonym
asthma; bronchial asthma

Research involving
Human

Sponsors and support

Primary sponsor: GlaxoSmithKline
Source(s) of monetary or material Support: GlaxoSmithKline BV

Intervention

Keyword: asthma, exacerbation, therapy, triple

Outcome measures

Primary outcome

Trough FEV1 at week 24.

Secondary outcome

Annualized rate of moderate/severe asthma exacerbations. FEV1 3h post dose

(week 24), Mean change from baseline in ACQ-7, SGRQ, total score at Week 24.

Mean change from baseline in Evaluating Respiratory Symptoms (E-RS) total score

over the first 24 weeks of the treatment period. Adverse effects.

Study description

Background summary

Inhaled corticosteroids, long-acting ß2-agonists (LABA) and long-acting muscarinic receptor antagonists (LAMA) are essential drugs for the treatment of more severe asthma.
Fluticasone furoate (FF) is an inhaled corticosteroid, umeclidinium (UMEC) is a LAMA and vilanterol (VI) is a LABA. The sponsor is currently developing these

three drugs in a once daily fixed combination as a dry powder for inhalation for the treatment of more severe asthma.
This new study has been designed in order to assess the effects of FF/UMEC/VI in subjects with insufficiently controlled asthma. The effects of 4 dosages of this combination will be compared to 2 dosages of the registered combination of FF/VI.
FF/UMEC/VI can be dosed once a day, thus improving treatment compliance.

Study objective

Primary:
To evaluate the effects of FF/UMEC/VI on lung function compared with FF/VI after 24 weeks of treatment
Secondary:
To assess the efficacy (exacerbations), FEV1 3h post dose, asthma symptoms, safety and tolerability.

Study design

Double blind multicenter parallel group study. Run-in period (Seretide) 3 weeks, stabilization period (FF/VI) 2 weeks, treatment period minimum 24 and maximum 52 weeks (dependent on the moment of randomization), follow-up period 1 week. Randomization (1:1:1:1:1:1) to once daily
* FF/UMEC/VI 100 mcg/62,5 mcg/25 mcg
* FF/UMEC/VI 200 mcg/31,25 mcg/25 mcg
* FF/UMEC/VI 100 mcg/31,25 mcg/25 mcg
* FF/UMEC/VI 200 mcg/62,5 mcg/25 mcg
* FF/VI 100 mcg/25 mcg
* FF/VI 200 mcg/25 mcg
2.250 subjects.

Intervention

Treatment with 1 of 4 dosages FF/UMEC/VI or 1 of 2 dosages FF/VI.

Study burden and risks

Risk: Adverse events of the study medication. Worsening of asthma due to changes in medication.
Burden:
8-10 visits in 32-60 weeks.
Based on 60 study weeks:
Physical examination: 3 times.
Blood draws: 4 times (15 ml blood).
Pregnancy test: 8 times.
Pulmonary function tests: 8 times (1-2 tests per occasion).

FeNO test onze.
ECG: 4 times.
Entire study period: 1. Daily FEV1/PEF measurements, 2. Diary symptoms and escape medication and 3. Diary adverse events, changes in medication, visits to other MDs.
Questionnaires: ACQ-5 weekly, others 4-6 times.
Optional: blood sample for pharmacogenetics, PK sampling day (4 samples in 3 h).

Contacts

Public
GlaxoSmithKline

Huis ter Heideweg 62
Zeist 3705 LZ
NL
Scientific
GlaxoSmithKline

Huis ter Heideweg 62
Zeist 3705 LZ
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

* Inadequately controlled asthma (ACQ-6 score *1.5) at Visit 2.
* A best pre-bronchodilator morning (AM) FEV1 *30% and <85% of the predicted normal

value at Visit 2. Predicted values will be based upon the ERS Global Lung Function Initiative.

Exclusion criteria

* Occurrence of a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear during the run-in period that led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject*s asthma status or the subject*s ability to participate in the study.
* Evidence of a severe exacerbation during screening or the run-in period, defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days (1) or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.
(1) For subjects on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required.
* Changes in asthma medication (excluding run-in medication and salbutamol inhalation aerosol provided at Visit 1).
* Pregnancy or breastfeeding.

Study design

Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Active
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	14-11-2016
Enrollment:	40
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	fluticasone furoate/umeclidinium/vilanterol
Generic name:	fluticasone furoaat/umeclidinium/vilanterol
Product type:	Medicine
Brand name:	Relvar
Generic name:	fluticasone furoate / vilanterol
Registration:	Yes - NL intended use

Ethics review

Approved WMO Date:	25-07-2016
Application type:	First submission
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	25-08-2016
Application type:	First submission
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	05-10-2016
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	06-10-2016
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	03-11-2016
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO Date:	04-11-2016
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	05-12-2016
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	08-12-2016
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	02-02-2017
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	03-02-2017
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	15-03-2017
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	17-03-2017
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	04-04-2017
Application type:	Amendment

Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	11-04-2017
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	02-08-2017
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	11-08-2017
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	11-09-2017
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	13-09-2017
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	11-05-2018
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	11-07-2018
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO

Date:	24-09-2018
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	25-09-2018
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2016-001304-37-NL
Other	http://www.gskclinicalstudyregister.com, nummer 205715
CCMO	NL58477.100.16